All In Biotech

Drug Trial Radar · NCT00342355

Antiretroviral Therapy for Advanced HIV Disease in South Africa

Randomized, Open-Label 2x2 Factorial Study to Compare the Safety and Efficacy of Different Combination Antiretroviral Therapy Regimens in Treatment Naive Patients With Advanced HIV Disease and/or CD4+ Cell Counts Less Than 200 Cells/MicroL

Last checked: Nov 19, 2026Latest source record: May 21, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,771 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,771

Actual

Start

Jan 2004

Primary completion

Mar 2008

Study completion Aug 2008

Sponsor

Sponsor type
NIH
First posted
Jun 21, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 14 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will determine how well four different antiretroviral drug therapies work in patients with advanced HIV disease. The trial is part of the South Africa-U.S. Project Phidisa Programme - a collaboration between the South African Military Health Service (SAMHS) of the South African National Defense Force (SANDF), the U.S. Department of Defense, and the U.S. National Institutes of Health - to help prevent HIV transmission among South African military and civilian employees and their families. Members of the SANDF with HIV infection may be eligible for this study. HIV-infected family members who are 14 years of age and older may also participate. All participants must have a CD4 count of less than 200 or an AIDS-defining illness. Participants are randomly assigned to one of the following four antiretroviral drug regimens, which require taking 5 pills or more every day: * AZT (zidovudine) + ddl (didanosine) + EFV (efavirenz) * AZT (zidovudine) + ddl (didanosine) + r/LPV (lopinavir/ritonavir) * D4T (stavudine) + 3TC (lamivudine) + EFV (efavirenz) * D4T (stavudine) + 3TC (lamivudine) + r/LPV (lopinavir/ritonavir) Patients are followed for up to 6 years. Clinic visits are scheduled once a month for the first 3 months and then once every 3 months for the next five years. Patients undergo a medical history, physical examination, and blood tests at each visit, and complete questionnaires of behavior, quality of life, and force readiness every year.

Conditions

  • HIV

Interventions

  • ZidovudineDrug

    600 mg once daily

  • StavudineDrug

    40 mg once daily

  • DidanosineDrug

    \<60 kg/125 mg twice daily or \>60kg/200 mg twice daily

  • LamivudineDrug

    300 mg once daily

  • EfavirenzDrug

    600 mg once daily

  • Lopinavir/RitonavirDrug

    r/LPV 400mg/100mg twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression to AIDS or Death in tx naïve Pts With Adv HIV dx in the Four Randomly Assigned Regimens.Time frame: January 2004 until March 31 2008

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • South African Military Health Services (SAMHS)

    Centurion, South Africa

  • Umtata Sickbay

    Eastaern Cape, South Africa

  • 3 Military Hospital

    Free State, South Africa

  • 1 Military Hospital

    Gauteng, South Africa

  • Mtubatuba SIckbay

    Kwazulu-Natal, South Africa

  • Phalaborwa Sickbay

    Limpopo, South Africa

  • 2 Military Hospital

    Western Cape, South Africa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.